Log In Sign up
The largest database of trusted experimental protocols

Anti mouse cd31 2502 antibody

Manufactured by BioLegend
Visit Supplier
Sourced in United States

Anti-mouse CD31 (#2502) antibody is a primary antibody that binds to the CD31 (also known as PECAM-1) protein expressed on mouse endothelial cells. CD31 is a cell adhesion molecule involved in the regulation of cell-cell interactions.

Automatically generated - may contain errors

Lab products found in correlation

4ebp1 thr70, by Cell Signaling Technology (2 mentions) Cdc2 tyr15, by Cell Signaling Technology (2 mentions) P27 sc 528, by Santa Cruz Biotechnology (1 mentions) Everolimus, by Novartis (1 mentions) Cyclin b1, by Cell Signaling Technology (1 mentions) Fgfr4, by Cell Signaling Technology (1 mentions) Survivin, by Cell Signaling Technology (1 mentions) Fgfr3, by Cell Signaling Technology (1 mentions) Frs2 α tyr439, by Cell Signaling Technology (1 mentions) Histone 3 ser10, by Cell Signaling Technology (1 mentions) Cleaved caspase 3, by Cell Signaling Technology (1 mentions) Cleaved parp, by Cell Signaling Technology (1 mentions) α tubulin, by Cell Signaling Technology (1 mentions) P70s6k, by Cell Signaling Technology (1 mentions) Infigratinib, by Selleck Chemicals (1 mentions) Sorafenib, by Selleck Chemicals (1 mentions) Cdc25c, by Cell Signaling Technology (1 mentions) 4e bp1, by Cell Signaling Technology (1 mentions) P mtor, by Cell Signaling Technology (1 mentions) Bevacizumab avastin, by Genentech (1 mentions)

Spelling variants of this product

Anti-CD31 (45 citations) Anti-mouse CD31 (11 citations) CD31 antibody (8 citations) Anti-CD31 antibody (4 citations) Anti-mouse CD31 antibody (3 citations)

2 protocols using anti mouse cd31 2502 antibody

1

Vinorelbine and Everolimus Combination Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols
Vinorelbine (Navelbine®) (10 mg/mL) was obtained from Pierre Fabre Medicament (Boulogne, France) and was dissolved in PBS to a final concentration of 0.375 mg/mL before use. Everolimus (RAD001) was obtained from Novartis (Basel, Switzerland) and dissolved in a vehicle (30% Captisol® in water) to achieve the appropriate concentration for the treatments.
Antibodies against AKT (#9272), p70S6K (#9202), survivin (#2803), S6R (#2217), Rb (#9313), Cyclin B1 (#4138), eIF4E (#9742), Cdc25C (#4688), cleaved caspase 3 (#9661), cleaved caspase 7 (#9491), cleaved PARP (#5625), Cyclin D1 (#2978), Cdc2 (#9112), and α-Tubulin (#2144) and phosphorylation-specific antibodies against RB Ser807/811 (#9308), AKT Ser473 (#9271), mTOR Ser2448 (#5536), p70S6K Thr421/424 (#9204), S6R Ser235/236 (#4858), 4EBP1 Thr70 (#9455), Histone H3 Ser10 (#9701), Cyclin D1 Thr286 (#3300), Cdc25C Ser216 (#4901), Cdc2 Tyr15 (#9111), eIF4E Ser209 (#9741), and ERK1/2 Thr202/Tyr204 (#4370) were obtained from Cell Signaling Technology (Beverly, MA, USA). RKIP (#37-2100) was obtained from Invitrogen. p-Cdk2 Thr14/Tyr15 (sc-28435-R), ERK1/2 (sc-94), and p27 (sc-528) were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Anti-mouse CD31 (#2502) antibody was purchased from BioLegend (San Diego, CA, USA).
Huynh H., Ng W.H, & Soo K.C. (2023). Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 25(1), 17.
+ Open protocol
+ Expand
2

Antibody Panel for Cancer Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies against AKT (#9272), FGFR-3 (#4574), FGFR-4 (#8562), p70S6K (#9202), Survivin (#2803), Cdk2 (#2546), Cdc25C (#4688), Cyclin B1 (#4138), cleaved caspase 3 (#9661), cleaved PARP (#5625), Cdc2 (#9112), Rb (#9313), S6R (#2217), 4EBP1 (#9452) and α-tubulin (#2144) were obtained from Cell Signaling Technology, Beverly, MA, USA. Phosphorylation-specific antibodies against AKT Ser473 (#9271), FRS2-α Tyr439 (#3861), p70S6K Thr421/424 (#9204), S6R Ser235./236 (#2211), 4EBP1 Thr70 (#9455), Histone 3 Ser10 (#9701), Cdc2 Tyr15 (#9111), p-mTOR (#2971), p-Rb (#9308) and ERK1/2 Thr202/Tyr204 (#4370) were also obtained from Cell Signaling Technology, Beverly, MA, USA. The antibodies against FGFR-2 (sc-122), ERK1/2 (sc-94), FRS2-α (sc-17841), E2F1 (sc-251) and p27 (sc-528) were obtained from Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA. The antibody LYVE-1 (AB-2988) was obtained from EMD Millipore, Billerica, MA, USA. The anti-mouse CD31 (#2502) antibody was obtained from BioLegend, San Diego, CA, USA. Infigratinib and Sorafenib were purchased from Selleck Chemicals, Houston, TX, USA. Bevacizumab (Avastin) was from Genentech, Inc., South San Francisco, CA, USA.
Le T.B., Vu T.C., Ho R.Z., Prawira A., Wang L., Goh B.C, & Huynh H. (2020). Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 21(24), 9405.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!